Christoph Weber
President and CEO
Replay available
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call
Takeda Pharmaceutical Company Limited (NYSE: TAK) Q4 2024 earnings conference call, held 2025-05-08. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mirana Furuta
Chief Financial Officer
Julie Kim
U.S. Business Unit President
Andy Plump
President R&D
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Takeda Pharmaceutical Co. Ltd..
Replay transcript excerpt
WEBVTT 00:00:01.246 -- 00:00:04.773 Honjutsu wa taihen o isogashii naka, Takeda Yakuhin Kogyo. 00:00:04.773 -- 00:00:08.298 Thank you for taking time out of your very busy schedule to join our earnings announcement 00:00:08.298 -- 00:00:11.860 for FY24 for Takeda. 00:00:12.103 -- 00:00:15.188 I'm the Master of Ceremony, Head of IR. My name is O'Reilly. 00:00:15.188 -- 00:00:17.151 Thank you for this opportunity. 00:00:17.151 -- 00:00:20.215 And allow me to explain about the language setting first. 00:00:20.215 -- 00:00:25.823 Please find the button for language selection at the bottom of your Zoom window. 00:00:25.823 -- 00:00:28.307 If you wish to listen in Japanese, please select Japanese. 00:00:28.307 -- 00:00:31.651 If you wish to listen in English, please select the English channel. 00:00:31.651 -- 00:00:34.743 If you want to listen to the original, please turn it off. 00:00:34.743 -- 00:00:38.611 For those of you who wish to listen to this call in English, please select English in 00:00:38.611 -- 00:00:41.793 the Zoom language select button. 00:00:42.338 -- 00:00:45.421 Before starting, 00:00:45.725 -- 00:00:50.214 I'd like to remind everyone that we'll be discussing forward-looking statements within 00:00:50.214 -- 00:00:54.993 the meaning of the Private Securities Litigation Reform Act of 1995. 00:00:54.993 -- 00:01:00.682 Actual results may differ materially from those discussed today. 00:01:00.682 -- 00:01:05.390 The factors that could cause our actual results to differ materially are discussed in 00:01:05.390 -- 00:01:08.034 our most recent Form 20F 00:01:08.034 -- 00:01:11.780 and our other SEC filings. 00:01:11.780 -- 00:01:13.443 Please 00:01:13.443 -- 00:01:18.611 also refer to the important notice on page 2 of the presentation regarding 00:01:18.611 -...